Madrigal Pharmaceuticals Net Worth
Madrigal Pharmaceuticals Net Worth Breakdown | MDGL |
Madrigal Pharmaceuticals Net Worth Analysis
Madrigal Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Madrigal Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Madrigal Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Madrigal Pharmaceuticals' net worth analysis. One common approach is to calculate Madrigal Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Madrigal Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Madrigal Pharmaceuticals' net worth. This approach calculates the present value of Madrigal Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Madrigal Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Madrigal Pharmaceuticals' net worth. This involves comparing Madrigal Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Madrigal Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Madrigal Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Madrigal Pharmaceuticals' net worth research are outlined below:
| Madrigal Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (373.63 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Madrigal Pharmaceuticals currently holds about 211.77 M in cash with (324.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.38. | |
| Madrigal Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Why Is Madrigal Pharmaceuticals, Inc. Among the Worst Performing Biotech Stocks in 2024 |
Madrigal Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Madrigal Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Madrigal Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Madrigal Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Madrigal Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Madrigal Pharmaceuticals backward and forwards among themselves. Madrigal Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Madrigal Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 405.7 K | Artisan Partners Limited Partnership | 2024-09-30 | 306.8 K | Rock Springs Capital Management Lp | 2024-06-30 | 245.5 K | Bank Of America Corp | 2024-06-30 | 239.6 K | Braidwell Lp | 2024-09-30 | 183.8 K | Ubs Group Ag | 2024-06-30 | 173.2 K | Goldman Sachs Group Inc | 2024-06-30 | 171.5 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 162 K | Charles Schwab Investment Management Inc | 2024-09-30 | 148 K | Hhg Plc | 2024-06-30 | 2.5 M | Paulson & Company Inc | 2024-09-30 | 2 M |
Follow Madrigal Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.58 B.Market Cap |
|
Project Madrigal Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.73) | (0.77) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (0.92) | (0.88) |
When accessing Madrigal Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Madrigal Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Madrigal Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Madrigal Pharmaceuticals' management efficiency
Madrigal Pharmaceuticals has return on total asset (ROA) of (0.5225) % which means that it has lost $0.5225 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2976) %, meaning that it created substantial loss on money invested by shareholders. Madrigal Pharmaceuticals' management efficiency ratios could be used to measure how well Madrigal Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.61. The value of Return On Capital Employed is expected to slide to -0.77. At this time, Madrigal Pharmaceuticals' Total Assets are quite stable compared to the past year. Other Current Assets is expected to rise to about 3.3 M this year, although the value of Non Currrent Assets Other will most likely fall to about 719.9 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 21.69 | 20.61 | |
| Tangible Book Value Per Share | 21.69 | 20.61 | |
| Enterprise Value Over EBITDA | (11.43) | (12.00) | |
| Price Book Value Ratio | 10.67 | 11.20 | |
| Enterprise Value Multiple | (11.43) | (12.00) | |
| Price Fair Value | 10.67 | 11.20 | |
| Enterprise Value | 4.3 B | 4.6 B |
At Madrigal Pharmaceuticals, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 87.2058 | Revenue 76.8 M | Revenue Per Share 3.705 | Return On Equity (1.30) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Madrigal Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Madrigal Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Madrigal Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Madrigal Pharmaceuticals Corporate Filings
F4 | 22nd of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 15th of August 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Madrigal Pharmaceuticals Earnings per Share Projection vs Actual
Madrigal Pharmaceuticals Corporate Management
| Justin Drinkwine | Senior VP | Profile | |
| Thomas Hare | Senior Management | Profile | |
| Remy Sukhija | VP Officer | Profile | |
| PharmD MBA | Senior Affairs | Profile | |
| Mark Underwood | Senior Operations | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.02) | Revenue Per Share 3.705 | Return On Assets (0.52) | Return On Equity (1.30) |
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.